FDAsafety guidance72% confidence
Jubilant HollisterStier General Partnership - 723537 - 05/28/2026
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Merck.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Infectious Disease · HIV
- Sub-indication
- General
Related signal: Merck Partners with ADAP to Enhance Access to IDVYNSO for HIV Treatment